Companies / BIIB vs AMGN
BIIB vs AMGN: Biogen and Amgen
Biogen (BIIB) reported $9.9B in revenue against a 13.1% net margin, while Amgen (AMGN) reported $36.8B at a 21.0% net margin, most recently.
| Metric | BIIB | AMGN |
|---|---|---|
| Revenue | $9.9B | $36.8B |
| Net Income | $1.3B | $7.7B |
| Gross Margin | 75.7% | 67.2% |
| Operating Margin | 15.7% | 24.7% |
| EPS (Diluted) | $8.79 | $14.23 |
| Free Cash Flow | $2.1B | $8.1B |
| Total Debt | $6.3B | $54.6B |
| P/E Ratio | 20.0× | 23.0× |
| P/B Ratio | n/m | 20.4× |
| Stock Price | $244.12 | $463.61 |
Free: last 5 years
| Fiscal year | FY2007 🔒 | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIIB Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| AMGN Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |